Hims & Hers (HIMS) is a high-growth, execution-dependent opportunity; consider it only if you can tolerate sharp volatility and a potentially long wait for returns. Track subscriber and revenue growth, marketing efficiency, and adoption of Peptide Plus, branded GLP-1s, and international expansion before treating these potential drivers as proven. The discussion provides no standalone investment case for Novo Nordisk (NVO) or Eli Lilly (LLY).

Hims & Hers Health (HIMS)

• The speaker is bullish on Hims & Hers, describing it as a high-growth company with long-term potential, despite repeated share-price declines.
• Quarterly revenue was $890.4 million, versus an estimate of $893 million, and grew 49% year over year. The speaker viewed the shortfall as small, while noting that the stock had fallen about 33% since the prior quarter’s report and was volatile around the earnings release.
• The company has nearly 3 million monthly subscribers, according to the transcript. The speaker also cited international growth of more than 300%.
• The speaker said Hims & Hers paced marketing spending during the quarter, potentially reserving more for the Peptide Plus launch. They claimed marketing payback is well under a year; that is the speaker’s characterization, not independently verified in the discussion.
• Hims & Hers is now offering and fulfilling branded GLP-1 products from Novo Nordisk and Eli Lilly through its own pharmacy, rather than redirecting customers to Lilly Direct, the speaker said.
• The company announced a Peptide Plus offering expected later in the month. The speaker speculated it might launch the following week, but that was not presented as a confirmed date.
• Andrew Huberman was announced as joining the board. The speaker sees his health-focused audience and association with peptides as a potential fit for the company’s social-media-led marketing.
• The speaker also pointed to the Eucalyptus acquisition, international expansion, and potential growth in testosterone replacement therapy (TRT) as parts of Hims & Hers’ opportunity.
• The speaker cautioned that the stock could remain undervalued for years. No price target was given.

Takeaways

• The discussion presents HIMS as a high-growth, execution-dependent investment rather than one to assess mainly on current earnings. Investors may want to track revenue growth, subscriber trends, marketing efficiency, and whether new offerings gain traction.
• The small revenue miss and sharp share-price reaction highlight volatility and the risk of expectations resetting. Consider whether you can tolerate that volatility and a potentially long wait for the market to recognize the company’s growth.
• Peptide Plus, branded GLP-1 fulfillment, international expansion, and TRT are potential growth drivers discussed—but the transcript does not establish how much revenue or profit they will generate.

Novo Nordisk (NVO)

• Novo Nordisk’s branded GLP-1 products were mentioned as available through Hims & Hers’ platform and pharmacy.
• The discussion focused on Hims & Hers’ distribution and metabolic-health opportunity, not on Novo Nordisk’s own financial outlook or valuation.

Takeaways

• The transcript offers no specific buy or sell view on NVO. It identifies Hims & Hers as a channel for Novo’s branded products, but does not assess the commercial impact on Novo.

Eli Lilly (LLY)

• Eli Lilly’s branded GLP-1 products were also described as available through Hims & Hers. The speaker specifically mentioned Zepbound being sold and fulfilled through the Hims & Hers platform.
• The speaker framed this arrangement as a meaningful change from redirecting customers to Lilly Direct.

Takeaways

• The transcript provides no standalone investment thesis or recommendation for LLY. The relevant insight is the distribution relationship with Hims & Hers; its financial significance for either company was not quantified.

Peptide and TRT Telehealth

• The speaker sees peptide-based services and testosterone replacement therapy as potential areas for Hims & Hers to expand into more complex care.
• Huberman’s board appointment was presented as relevant to the peptide opportunity because of his public profile and association with the subject.
• The speaker compared TRT’s established demand in in-person clinics with the possibility of delivering it through Hims & Hers’ online platform.

Takeaways

• These are potential business opportunities, not demonstrated results in the transcript. Watch for confirmed launch details and evidence of customer adoption before assuming they will materially boost growth.
• The discussion does not provide specific timelines for TRT, revenue expectations, or detailed risks for either offering.